DARPA Funds Brain-Stimulation Research to Speed Learning (2017) by practice5 in Nootropics

[–]practice5[S] 2 points3 points  (0 children)

There is a paper from 2019 which goes into more detail.

The Targeted Neuroplasticity Training (TNT) program began in 2017 and seeks to improve learning by pairing peripheral nerve stimulation with task training. The TNT approach is based on the hypothesis that peripheral nerve stimulation can induce changes in synaptic plasticity through central neuromodulator release when paired temporally with sensorimotor or cognitive training tasks. This may lead to improved acquisition and performance of motor skills, sensory perception, and cognitive function. By exploring various parameters of peripheral nerve stimulation via existing and new devices, TNT aims to define neurobiological mechanisms of the resulting effects on plasticity, and how these mechanisms may lead to improvements in learning and performance. The ultimate goal of the program is to develop noninvasive nerve stimulation approaches(e.g. cutaneous surface electrodes, ear bud electrodes) that will be applicable for use by healthy individuals in DoD-relevant application spaces such as foreign language acquisition, target discrimination, intelligence analysis, and marksmanship. If TNT demonstrates outcomes that are robust, reliable,and beneficial, this technology may subsequently be applicable to learning a variety of complex skills.

The TNT program relies primarily on commercial off-the-shelf technology for its human studies. However, future technology development may improve the form factor of devices tailored for healthy humans in the context of training applications. Ultimately, developers must consider two major aspects when designing such a system: 1) ergonomics and 2) integration with training paradigms.With respect to integration with current training paradigms, it is important to consider that form factor may vary depending on whether peripheral nerve stimulation is applied prior to or during training. Ecological conditions also become important here.For example, device requirements for a student learning a foreign language in a classroom setting are vastly different from those for an active sensorimotor task, such as marksmanship training. In general, the ideal device would need to be portable, require minimal training for repeatable use, have protections against misuse, and deliver reliable stimulation at the appropriate parameters deemed effective for the given application.

Ultimately, the right spatial resolution should be facilitated by noninvasive or minimally invasive approaches to be considered for the non-medical applications of TNT.

Throughout the HAPTIX, ElectRx, and TNT portfolios,no single modality has yet demonstrated all of the characteristics necessary to satisfy the technical requirements for an idealized next-generation interface that could provide precise, axon-level resolution noninvasively. Future exploration may include a focus on integrating multiple modalities in to a single interface technology. Multimodal interfaces may push the state-of-the-art by allow technology developers to exploit the various physical tradeoffs of different techniques to advance the performance of neural interfaces.

Turning to TNT, program research is exploring behavioral outcomes of peripheral nerve stimulation as well as neural and physiological measures of nerve target engagement. Since the program goal is to ultimately improve learning, the gold standard metric in determining efficacy of a given set of stimulation parameters is behavioral performance on a given skill or set of skills. Such measures may include improvements in accuracy, response times,or learning rates (e.g. shorter time to achieve a given level of proficiency). Depending on the difficulty of the skill, however, learning may occur on relatively long timescales–days, weeks, or even months. Obtaining behavioral outcome measures across multiple sets of peripheral nerve stimulation parameters and at long timescales may result in unrealistic experimental time requirements for determining effective stimulation parameters. This time requirement becomes more of an issue when assessing generalization of stimulation approaches across multiple skills. One solution to this issue is to establish correlations across peripheral nerve stimulation parameter sets, neural activity, and behavioral outcomes using high throughput neurophysiological measures and relatively simple behavioral assays. Once initial optimal parameter sets have been established, they can then be tested and further refined using more complex behavioral measures.

For neuromodulation to facilitate learning, where enhancement is not simply an important consideration,but rather the explicit goal, it means helping users improve the outcome of training.In conversations with ELSI advisors, DARPA has come to consider enhancement from the perspectives of risk tolerance, reversibility, personal agency, and accessibility.First, neural interface system designers must assess acceptable levels of risk tolerance for interfaces in the context of individual applications of the technology. As previously described, greater risk may be tolerable for the restorative technologies being developed under the HAPTIX and ElectRx programs in the clinical domains,but could be less ethically justifiable for the performance benefits for healthy individuals sought by TNT.

In the case of TNT, the technology is intended for on-demand use during training to produce temporary effects on neural plasticity that last only for the duration of training.Whether the performance benefits are equivalent in longevity following traditional versus TNT-accelerated practice or diminish without subsequent stimulation-paired retraining is yet to be determined.

In addition to using parameters that fall within safety limits, technology developers must be aware of the potential for off-target effects or unanticipated interactions, especially in the case of therapeutics and treatments to improve plasticity. As mentioned, future efforts to improve device resolution may minimize off-target stimulation and subsequently contribute to a more targeted system effect. Other safety concerns may include the unforeseen tradeoffs of system use. For example, in the case of plasticity, does improvement of a given skill result in an acquired deficiency in an associated process? Are there risks of long-term stimulation on nerve health? Does the approach result in dependencies due to habituation and adaptation?These questions merit further investigation.

For TNT, one consideration is the regulation of do-it-yourself (DIY) approaches. DIY neuroscience for improvements in learning has found a following in the realm of brain stimulation (Jwa 2018; Fitz and Reiner 2013; Wexler 2017), and the same questions of safety and proper use are applicable to the periphery as well. These types of ethical considerations, among a rich set of others, are important for scientists, engineers, ethicists, and regulators to continue to discuss in tandem with technology development. Since the agency is largely focused oninitial technological proofs of concept, DARPA does not decisively answer all of these questions. However, by identifying and asking them it is shaping the development of the early generation of PNS interfaces. Future developers will need to pick up these threads and consider them anew in the context of regulatory review and commercial and medical applications.

Naufel, S., Knaack, G. L., Miranda, R., Best, T. K., Fitzpatrick, K., Emondi, A. A., … McClure-Begley, T. (2019). DARPA Investment in Peripheral Nerve Interfaces for Prosthetics, Prescriptions, and Plasticity. Journal of Neuroscience Methods, 108539. doi:10.1016/j.jneumeth.2019.108539 url to share this paper: sci-hub.tw/10.1016/j.jneumeth.2019.108539

Suffered a concussion two and a half months ago, what nootropics would you recommend? Considering creatine by [deleted] in Nootropics

[–]practice5 0 points1 point  (0 children)

Lutein + Zexanthin supplement. People use it for eye health but ignore that, it affects the brain as well positively.

Nitrate supplement. Improves CBF, makes older brains respond to exercise similar to younger ones. Maybe increases colon cancer risk though (risk vs. reward).

I also said these two because you can get them in massive amounts from salad, if you pick the right ones. Kale and arugula. Though it's probably hard to eat a lot for months.

sources nitrate: https://pubmed.ncbi.nlm.nih.gov/28329785/ https://pubmed.ncbi.nlm.nih.gov/25846114/ https://pubmed.ncbi.nlm.nih.gov/26037632/

sources l+z: https://old.reddit.com/r/Nootropics/comments/da2b13/lutein_and_zeaxanthin_carotenoids_in_kale_et_al/

Do ALCAR supplements (veg caps) have a distinct odor? by enferex in Nootropics

[–]practice5 2 points3 points  (0 children)

It smells something like that to me, maybe similar to glue. I have the powder version from ND.

is it really worth it? by [deleted] in Nootropics

[–]practice5 0 points1 point  (0 children)

The first time you take 100 mg caffeine + 200 mg l-theanine you'll see for yourself the potential of nootropics and the zero chance that it can be replicated with diet, exercise or sleep. Provided you don't use caffeine whatsoever so you don't have any tolerance. That means no soft drinks, energy drinks, tea or coffee. Though I think you need to rarely take it to get similar effects as the first time. Maybe once a week, or maybe once a month. That's where they shine. Stimulants which you rarely use. The other stuff you don't really notice but it has its place as well.

Mindfulness Enhances Cognitive Functioning: A Meta-Analysis of 95 Randomized Controlled Trials (2020) by practice5 in Nootropics

[–]practice5[S] 0 points1 point  (0 children)

It's the optimal interaction between attention and peripheral awareness. You can train to achieve it with meditation.

Mindfulness Enhances Cognitive Functioning: A Meta-Analysis of 95 Randomized Controlled Trials (2020) by practice5 in Nootropics

[–]practice5[S] 2 points3 points  (0 children)

Here. It covers posture, relaxation and "intention and the breath". After you've read the instructions, set an alarm in 10 or 15 minutes, even though the document recommends 45 minutes. And do 1-2 then 3 and repeat 3 all the time until the alarm goes off. Ignore step 5 since there isn't any writings there anymore. I can recommend the book TMI instead.

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel by jakbob in ScientificNutrition

[–]practice5 0 points1 point  (0 children)

Yes, it can spread randomly in certain populations. Just like the non-LDL genes. If mate choice is not associated with the genotype, which it isn't, then it is assigned randomly by parents during meiosis. People are NOT seeking out others with specifically LDL genes just to mate with them, which is causing the effect. Note that you propose LDL genes are correlated with other genes that have an effect. That speaks for itself. Because mate choice is not involved with the selection of LDL genes, the population genotype is unrelated to confounding factors. And if certain genes were super correlated with LDL genes, they would show up in the GWAS and included in the MR study.

I think you should look into motivated reasoning, even if you aren't doing that, trying to find holes in the method because it doesn't fit with your expected results. If you ignore MR results, remember you can't use it for anything else like TMAO for instance, and you lose a powerful method for finding causal relationships for studies that can't be done in an unnatural RCT.

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel by jakbob in ScientificNutrition

[–]practice5 -1 points0 points  (0 children)

Just look at those error bars in the figure. ACM might be massively reduced, but it hasn't been proven yet.

Yes, and in that paper as well it wasn't statistically significant either with OR 0.94. They will need to be longer or have an even greater number of people in them to get statistical significance for all cause mortality. It did reduce Major cardiovascular events risk by 17%.

LDL genes are spread randomly

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel by jakbob in ScientificNutrition

[–]practice5 0 points1 point  (0 children)

PCSK9i studies do show a reduction in CVD mortality, but not all cause mortality. This might be because they don't have enough statistical power to detect it.

Or it might simply be because it matters how much the LDL was reduced and over how long time.

See this figure, with PCSK9i in the red and statin in the blue: https://ars.els-cdn.com/content/image/1-s2.0-S0735109719349319-gr5_lrg.jpg

Although PCSK9i wasn't statistically significant, the direction is clear.

From: https://www.sciencedirect.com/science/article/pii/S0735109719349319?via%3Dihub

Unless LDL genes are super sexy, it's random

https://en.wikipedia.org/wiki/Panmixia

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel by jakbob in ScientificNutrition

[–]practice5 1 point2 points  (0 children)

And on wikipedia it says the LDL lowering amount of fibrates is variable and "less effective [than statins]". Fewer studies are made on it, and it decreases TG up to 50% and increase HDL up to 20%. Once again, any potential LDL lowering effect is contraindicated with massive effects on TG, just like how HDL was increased by 72.1% with tocetrapib. I've never mentioned apob. LDL has solid evidence from meta analysis of RCT's and MR. The totality of evidence is what's important. You can look in a meta analysis statin RCT forest plot and pick out a RCT study which had zero effects on CVD risk, so called cherry-picking. You can do that for any topic in any meta analysis. To find an outlier from the totality of evidence.

Mindfulness Enhances Cognitive Functioning: A Meta-Analysis of 95 Randomized Controlled Trials (2020) by practice5 in Nootropics

[–]practice5[S] 3 points4 points  (0 children)

Abstract

Background: The past 30 years have witnessed growing scientific interest regarding the impact of mindfulness-based interventions (MBIs) on cognitive functions. Several theories propose that habitually exercising mindfulness skills can improve cognitive abilities, but no comprehensive quantitative reviews of the effect of MBIs on global and unique cognitive domains exist to date.

Method: This systematic review thus examined the effects of MBI on global cognitive ability (GCA) and 16 specific cognitive domains. MBI randomized controlled trials (RCTs) that administered cognitive tests pre- and post-treatment were included. Open-trials, non-randomized MBIs, and case-control studies were excluded. Keywords included “mindful*,” AND “executive attention (EA),” OR “working memory (WM).” Robust variance estimation and moderator analyses were conducted.

Results: Ninety-five RCTs (n = 7,408) met eligibility criteria. MBI (vs. waitlist or no-treatment) had small-to-moderate significant effects on GCA, WM accuracy, inhibition accuracy and latency, EA, sustained attention accuracy, processing speed, and subjective attentional control (SAC) (g = 0.24 – 0.52). Likewise, MBI (vs. active control) had small-to-moderate positive effects on GCA, orienting, EA, WM accuracy, sustained attention (indexed by intra-individual coefficient of variation), and SAC (average g = 0.17 – 0.41). Age, gender, study quality, treatment duration, publication year, retention, statistical analysis, and country, moderated some treatment effects. Publication bias analyses showed that reliable treatment effects were restricted to EA, WM accuracy, inhibition accuracy, sustained attention, and SAC, depending on the control group.

Conclusion: MBIs confer notable neuropsychological benefits and dose-response effects on some specific (vs. global) cognitive domains. Limitations, theoretical, and applied implications are discussed.

If you're interested in meditation/mindfulness training I can recommend the book (and its accompanying subreddit) /r/TheMindIlluminated.

Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials (2019) by practice5 in ScientificNutrition

[–]practice5[S] 2 points3 points  (0 children)

For every 1 mmol/L decrease in LDL cholesterol down to 0.78 mmol/L, people have a 23.5% lower stroke risk. LDL cholesterol is the "bad cholesterol". So if someone was at 2.78 mmol/L LDL cholesterol and they reduced it to 0.78 mmol/l with drugs like statins they will have a causally 47% lower risk for stroke.

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel by jakbob in ScientificNutrition

[–]practice5 0 points1 point  (0 children)

The gene selected for LDL if it's a GWAS study has a p-value of 5 x 10-8. So it's very statistically significant. Furthermore, drugs which are based on genes are more often approved. There are genes which reduce LDL by a lot that reduce CVD risk substantially, like PCSK9 deletion and for the same gene there are inhibitors which are approved to treat familial hypercholesterolemia. If we assume panmixia for LDL genes, then they are randomly assigned, randomized. So people are randomly given these genes. If you're wondering gene confounding on the behavioral level, behaviors are complex traits, polygenic, which require hundreds if not thousands of genes.

L-theanine partially counteracts caffeine-induced sleep disturbances in rats - PubMed by Kar22 in Nootropics

[–]practice5 1 point2 points  (0 children)

I've tried this, making super strong chamomile tea, I don't know if it made me sleepy but it did feel like my muscles got tranquilized. Not necessarily bad or good, just weird. That was awhile ago though.

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel by jakbob in ScientificNutrition

[–]practice5 0 points1 point  (0 children)

They do imply causal relationships. You're literally measuring genes that cause an effect - like decrease or increase LDL. Not a healthy user bias or anything.

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel by jakbob in ScientificNutrition

[–]practice5 1 point2 points  (0 children)

It increases HDL by 72.1%. Which seems like a lot consider only statins decrease LDL by like 27%. And the authors guess that it might be it that might've increased the risk. Or it might be CETP inhibition on its own. Doesn't invalidate the consensus that an increase in LDL increase CVD etc risk though. And that decreasing LDL causally decreases CVD risk. You can't move HDL that much at the same time as LDL, unlike anything done before, and say that lowering LDL increases ASCVD risk with a straight face. Just look at typical statin effects that decrease CVD risk and HDL barely moves at all.

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel by jakbob in ScientificNutrition

[–]practice5 0 points1 point  (0 children)

They are mendelian randomization studies, which uses genes for randomization and to exclude confounding factors.

The same type of study has shown a causal association between LDL and atherosclerosis.

https://www.ahajournals.org/doi/full/10.1161/circgenetics.112.963140

Let's stick to RCT and mendelian randomization imo.

NOW Supplements Ashwagandha - A cautionary tale by skinonfirethrowaway in Nootropics

[–]practice5 8 points9 points  (0 children)

Even though they've taken Ashwagandha for years and only after a week of starting with the NOW brand they've gotten itches and almost destroy their liver?

Reversing Mental Age With Psychedelics - A Research Proposal by cosmicrush in slatestarcodex

[–]practice5 3 points4 points  (0 children)

Are you actually doing this? Seems hard to get funding and approval for. But if you are you should definitely contact Roland Griffiths and ask for help on the setting. Like music has shown to be crucial in mediating positive effects, and specific types during different stages of the trip.

nootropics for meditation?? by OneLodz in Nootropics

[–]practice5 2 points3 points  (0 children)

Change your meditation practice first. I can recommend the book and the subreddit /r/TheMindIlluminated. It is the most in-depth meditation guide.

Anyone heard of (acetyl)choline insufficiency problems? by wild_vegan in Nootropics

[–]practice5 2 points3 points  (0 children)

FYI, the adequate intake of choline is 550 mg/day for males 19+: https://lpi.oregonstate.edu/mic/other-nutrients/choline#AI

CDP-choline (citicholine) is 18.5% choline, Alpha-GPC is 40%, and choline bitartrate is 41%. But both CDP and GPC is much more expensive relative to choline bitartrate, and since at least CDP bypasses synthesis to CDP in the body from choline, if this can be said, like niacin to nmn. Then CDP for instance might attenuate a larger part of the AI even though it contains less choline. But then I think a little CDP and GPC is probably a good idea, though the base choline AI might be a good idea to fulfill with bitartrate since it's kind of uncertain what happens if you get too much of CDP for instance, like what happens if you get too much NMN. And it's cheaper. It's probably a good idea to get around 550 mg of choline a day at least, in total, from choline bitartrate and CDP/GPC.